<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294255</url>
  </required_header>
  <id_info>
    <org_study_id>RIS-USA-T290</org_study_id>
    <nct_id>NCT00294255</nct_id>
  </id_info>
  <brief_title>Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania</brief_title>
  <official_title>Risperidone Plus Mood Stabilizer in the Treatment of Mixed Mania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the efficacy and tolerability of risperidone added to lithium,
      valproate or lamotrigine in patients experiencing a manic episode with depressive or
      irritable features.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study aims to assess the efficacy and tolerability of risperidone added to lithium,
           valproate or lamotrigine, or any combination of the three, in patients experiencing a
           manic episode with depressive or irritable symptoms.

        -  To assess the back ground and baseline features associated with response/non-response to
           risperidone plus mood stabilizer in patients with mania with depressive or irritable
           features.

        -  To assess the symptomatic dimensions of response of risperidone added to mood
           stabilizers in patients with mania with depressive or irritable features.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forty percent reduction in YMRS</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>twenty percent reduction in MADRS</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate, defined as final score of plus or minus eight on YMRS and MADRS</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive risperidone for up to 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>risperidone will be administered 1-3mg pills, each night, for up to 20 weeks</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM IV diagnosis of bipolar disorder, currently manic, or mixed manic

          -  YMRS score&gt;/= 16

          -  One or more of following:

               1. 3 MADRS depression items scoring &gt;/=3

               2. 3 BISS depression items scoring &gt;/=3

               3. YMRS irritability and aggressive items sum score&gt;/=4

          -  Taking lithium, valproate or lamotrigine at stable dose for 4 wks or longer, with
             adequate serum level

          -  age 18 and over

          -  Male or female

          -  Inpatient or outpatient

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Singh, MD</last_name>
    <role>Study Director</role>
    <affiliation>UT-SanAntonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2006</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Vivek Singh</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>mixed mania</keyword>
  <keyword>depression</keyword>
  <keyword>irritability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

